BrainStorm to Present at Multiple Scientific Conferences in October

NEW YORK & PETACH TIKVAH, Israel--(BUSINESS WIRE)--

BrainStorm Cell Therapeutics (BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that it is presenting at multiple scientific conferences this month.

Israel Stem Cell Society 5thInternational Stem Cell Meeting

Professor Dani Offen, BrainStorms Chief Scientific Advisor, will present at the 5th International Stem Cell Meeting sponsored by the Israel Stem Cell Society, October 8th-9th in Jerusalem. Prof. Offen will be making a poster presentation on October 8th at 17:30, and an oral presentation on Oct 9th at 17:15.

Israel Braintech 2013

Professor Dani Offen, BrainStorms Chief Scientific Advisor, will present at the Israel Braintech 2013 Meeting, October 14th-15th in Tel Aviv. The meeting is sponsored by Israel Brain Technologies (IBT), a non-profit organization inspired by the vision of Israeli President Shimon Peres to promote Israels neurotechnology innovation hub. Prof. Offens oral presentation will be part of the session entitled: A Spotlight on the Israeli NeuroTech Industry, October 15th at 12:15.

Israel A.L.S Research Association

Professor Dimitrios Karussis, Principal Investigator of BrainStorms clinical trials at Jerusalems Hadassah Medical Center, will present at the Israel A.L.S Research Association (IsrA.L.S) Conference, From the Lab to the Clinic: An Overview of Current ALS Research in Israel, to be held October 30th at the Weizmann Institute of Science, Rechovot, Israel. Prof. Karussis oral presentation will be at 10:45 a.m.

About BrainStorm Cell Therapeutics, Inc.

BrainStorm Cell Therapeutics Inc. is a biotechnology company engaged in the development of first-of-its-kind adult stem cell therapies derived from autologous bone marrow cells for the treatment of neurodegenerative diseases. The Company holds the rights to develop and commercialize its NurOwn technology through an exclusive, worldwide licensing agreement with Ramot, the technology transfer company of Tel Aviv University. For more information, visit the companys website at http://www.brainstorm-cell.com.

View post:
BrainStorm to Present at Multiple Scientific Conferences in October

Q Therapeutics CEO to Present at Third Annual Regen Med Partnering Forum at the 2013 Stem Cell Meeting on the Mesa

SALT LAKE CITY, UT--(Marketwired - Oct 8, 2013) - Q Therapeutics, Inc., an emerging biotechnology company developing innovative cell therapy products for the treatment of debilitating diseases of the central nervous system, today announced that Deborah Eppstein, PhD, President and CEO, is scheduled to present at the Third Annual Regen Med Partnering Forum at the 2013 Stem Cell Meeting on the Mesa.

The 2013 Stem Cell Meeting on the Mesa is a three-day conference aimed at bringing together senior members of the regenerative medicine industry with the scientific research community to advance stem cell science into cures.The meeting features a nationally recognized Scientific Symposium, attended by leading scientists and researchers, in conjunction with the industry's premier annual Regen Med Partnering Forum.Combined, these meetings attract over 800 attendees from around the globe, fostering key partnerships through one-on-one meetings while also highlighting clinical and commercial progress in the field.

EVENT AT A GLANCE:

Date: October 14, 2013

Time: 11:45 AM PT

Location: Estancia La Jolla Hotel & Spa La Jolla Ballroom AB 9700 North Torrey Pines Road La Jolla, California

To learn more or to register for the Third Annual Regen Med Partnering Forum at the 2013 Stem Cell Meeting on the Mesa, please visit http://www.stemcellmeetingonthemesa.com.Registration is required.

About Q Therapeutics, Inc. Headquartered in Salt Lake City, Utah, Q Therapeutics, Inc. is a fully reporting, non-trading company, engaged in developing adult stem cell therapies to treat debilitating diseases of the central nervous system.The Company's first product, Q-Cells, is a cell-based therapeutic intended to restore or preserve normal activity of neurons by providing essential support functions that occur in healthy central nervous system tissues.Q-Cells may be applicable to a wide range of central nervous system diseases, including demyelinating conditions such as multiple sclerosis, transverse myelitis, cerebral palsy and stroke; as well as other neurodegenerative diseases and injuries, such as ALS (Lou Gehrig's disease), spinal cord injury, Parkinson's disease and Alzheimer's disease.Q Therapeutics' initial clinical target is ALS, with a first IND submission expected in 2014.For more information, visit http://www.qthera.com.

Read the original post:
Q Therapeutics CEO to Present at Third Annual Regen Med Partnering Forum at the 2013 Stem Cell Meeting on the Mesa

Stem cells delivered by patch repair damage after cardiac arrest

Stem cells delivered by patch effective in repairing cardiac damage weeks after heart attack occurs

A new study released in STEM CELLS Translational Medicine shows that in rats, treating a heart attack with stem cells even weeks after the attack occurred can halt deterioration and help the heart regenerate itself. In addition, the doctors delivered the cells using a patch that resulted in a higher survival rate for the stem cells and more of them migrating into the damaged tissue, where they went to work creating new blood vessels.

The team, from the University of Louisvilles Cardiovascular Innovation Institute (Louisville, KY), had previously shown in rat studies that stem cell treatment immediately following an attack aided recovery by improving blood flow in the smallest vessels of the heart. This time the goal was to determine if the treatment was still effective if applied later in time.

We also were seeking a more efficient delivery method for the stem cells by utilizing the heart patch model. Most studies employing an injection of stem cells encounter swift cell death or cell washout from the target tissue, said Amanda LeBlanc, Ph.D., who led the investigation along with Stuart Williams, Ph.D., the institutes executive and scientific director.

They tested their theory by applying a patch seeded with stem cells harvested from the animals own adipose (fat) tissue and then cultured in the lab. They implanted the seeded patches into one group of rats two weeks after the animals had a heart attack, while another group received the patch without stem cells (to gauge whether any effects might be due to the body's response to a foreign material or whether the biomaterial itself was helping the heart pump more efficiently, regardless of cells). Two more groups of rats with induced heart attacks were given no treatment, and were carried out for two and six weeks as controls.

This approach allowed us to study the progressive and sometimes irreversible pathological changes that occur weeks to months following an attack, such as cellular death, the beginning of scar tissue formation and thinning of the outer left ventricle wall, Dr. Williams explained.

When they compared the results, they found that the cell patch treatment indeed stabilized the heart, preventing or halting any worsening of cardiac function and restoring blood flow to the small blood vessels. This is why I refer to our cell patch as a pause button, because once it was applied the heart didn't progress into worse function like the patch group without cells and the untreated six-week group, Dr. LeBlanc said.

That led us to conclude that the clinical potential of an autologous patch that is, a patch seeded with the patients own stem cells using adipose-derived cells is high, as the patch may be used in conjunction with existing heart attack therapies to promote small vessel survival and/or growth of new vessels following the attack, she added.

This study, and the authors previous research, both in rats, lays important groundwork in addressing such issues as the best delivery method of cells and how long after a heart attack treatment might be beneficial, said Anthony Atala, M.D., editor of STEM CELLS Translational Medicine and director of the Wake Forest Institute for Regenerative Medicine.

STEM CELLS Translational Medicine

Follow this link:
Stem cells delivered by patch repair damage after cardiac arrest

Global Stem Cells Group, Inc. Announces Launch of Plasma Plus Platelet Rich Plasma Therapy Services in Dominican …

Miami (PRWEB) October 07, 2013

The Global Stem Cells Group, Inc. has announced the launch of Plasma Plus medical services company in the Dominican Republic. Plasma Plus provides certified medical professionals, top of the line equipment, FDA approved protocols for hospitals, clinics and physicians, and protocol-specific equipment and consumables for application of platelet rich plasma therapy (PRP.)

Plasma Plus also assigns a qualified, certified health care professional to perform the PRP extraction and preparation procedures. Clients need only apply the therapy where needed to achieve the rejuvenating, regenerating and revitalizing results of PRP therapy, eliminating excess overhead costs, need for equipment purchases and preoccupation with maintaining protocol standards.

The benefits of PRP treatments extend through a wide and diverse group of medical fields, from cosmetic surgery to dentistry; Plasma Plus is committed to making PRP an available and cost-effective treatment option for medical professionals.

The companys product line includes:

The Plasma Plus equipment line includes:

For more information on Plasma Plus medical services, products and equipment, visit the Plasma Plus website, email info(at)www(dot)plasmaplusonline(dot)com(dot)do or call 849.943.2988.

About Plasma Plus:

Plasma Plus is an innovative, turn-key medical service company providing certified professionals, state-of-the-art equipment, and FDA approved protocols and kits for application of platelet rich plasma therapy (PRP). Plasma Plus technicians are trained and certified by a qualified team of medical professionals that includes physicians and nurses. Staffed by physicians, medical consultants and leading scientific researchers in the field to provide patients with the leading platelet rich plasma therapy.

PRP treatments utilize the bodys own resources to stimulate growth and regeneration with an overabundance of growth factors derived from platelets.

See original here:
Global Stem Cells Group, Inc. Announces Launch of Plasma Plus Platelet Rich Plasma Therapy Services in Dominican ...

BrainStorm to Present at 2013 Stem Cell Meeting on the Mesa Organized by CIRM, ARM and Sanford Consortium

NEW YORK & PETACH TIKVAH, Israel--(BUSINESS WIRE)--

BrainStorm Cell Therapeutics (BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that Dr. Adrian Harel, Director R&D, will present at the 3rd Annual Regen Med Partnering Forum, part of the Stem Cell Meeting on the Mesa to be held October 14-16 in La Jolla, CA.

Organized by the Alliance for Regenerative Medicine (ARM), the California Institute for Regenerative Medicine (CIRM) and the Sanford Consortium for Regenerative Medicine, the 2013 Stem Cell Meeting on the Mesa is a three-day conference aimed at bringing together senior members of the regenerative medicine industry with the scientific research community to advance stem cell science into cures. The Regen Med Partnering Forum, held October 14 & 15 at the Estancia La Jolla Hotel, is the only partnering meeting organized specifically for the regenerative medicine and advanced therapies industry.

The meeting also features a nationally recognized Scientific Symposium, held October 16 at the Salk Institute for Biological Studies, showcasing leading academic research in the field of regenerative medicine. Combined, these meetings attract over 800 attendees from around the globe, fostering key partnerships through one-on-one meetings while also highlighting clinical and commercial progress in the field.

The following are specific details regarding BrainStorms presentation at the conference:

Event: Regen Med Partnering Forum 2013 Stem Cell Meeting on the Mesa Date: Monday, October 14, 2013 Time: 10:45 am Location: Estancia La Jolla Hotel & Spa, 9700 North Torrey Pines Road, La Jolla, CA 92037

A live video webcast of all company presentations will be available at: http://stemcellmeetingonthemesa.com/webcast/ and will also be published on ARMs website shortly after the event.

About BrainStorm Cell Therapeutics, Inc.

BrainStorm Cell Therapeutics Inc. is a biotechnology company engaged in the development of first-of-its-kind adult stem cell therapies derived from autologous bone marrow cells for the treatment of neurodegenerative diseases. The Company holds the rights to develop and commercialize its NurOwn technology through an exclusive, worldwide licensing agreement with Ramot, the technology transfer company of Tel Aviv University. For more information, visit the companys website at http://www.brainstorm-cell.com.

Safe Harbor Statement

Visit link:
BrainStorm to Present at 2013 Stem Cell Meeting on the Mesa Organized by CIRM, ARM and Sanford Consortium